Sign Up Today and Learn More About Tachyon Therapeutics Stock
Invest in or calculate the value of your shares in Tachyon Therapeutics or other pre-IPO companies through EquityZen's platform.
Tachyon Therapeutics Stock (TATH)
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
About Tachyon Therapeutics Stock
Founded
2019
Headquarters
San Francisco, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Tachyon Therapeutics Press Mentions
Stay in the know about the latest news on Tachyon Therapeutics
Aptevo Participating in the BIO International Convention
biospace • Jun 16, 2025
Aptevo Participating in the BIO International Convention
newswire • Jun 13, 2025
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
biospace • Apr 22, 2025
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
streetinsider • Apr 21, 2025
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
newswire • Apr 07, 2025
Tachyon Therapeutics Management
Leadership team at Tachyon Therapeutics
Chief Executive Officer
Frank Perabo
Board Member
Jeffrey Stafford
Join now and verify your accreditation status to gain access to:
- Tachyon Therapeutics Current Valuation
- Tachyon Therapeutics Stock Price
- Tachyon Therapeutics Management
- Available deals in Tachyon Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Tachyon Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Tachyon Therapeutics Revenue and Financials
- Tachyon Therapeutics Highlights
- Tachyon Therapeutics Business Model
- Tachyon Therapeutics Risk Factors
- Tachyon Therapeutics Research Report from SACRA Research
Trading Tachyon Therapeutics Stock
How to invest in Tachyon Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Tachyon Therapeutics through EquityZen funds. These investments are made available by existing Tachyon Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Tachyon Therapeutics stock?
Shareholders can sell their Tachyon Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
